OPKO Health, Inc. Operating Lease, Payments
OPKO Health, Inc. (OPK) reported Operating Lease, Payments of $7.60 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-28
- OPKO Health, Inc. operating lease, payments for the quarter ending 2026-06-30 was $3.86M, a 9.08% decline year-over-year.
- OPKO Health, Inc. operating lease, payments for the quarter ending 2026-03-31 was $3.73M, a 7.83% increase year-over-year.
- OPKO Health, Inc. operating lease, payments for the quarter ending 2025-12-31 was $3.77M, a 54.78% increase year-over-year.
- OPKO Health, Inc. operating lease, payments for the quarter ending 2025-09-30 was $3.16M, a 47.28% decline year-over-year.
- OPKO Health, Inc. operating lease, payments for fiscal 2025 was $14.64M, a 16.53% decline from fiscal 2024.
- OPKO Health, Inc. operating lease, payments for fiscal 2024 was $17.54M, a 8.84% increase from fiscal 2023.
- OPKO Health, Inc. operating lease, payments for fiscal 2023 was $16.11M, a 0.98% decline from fiscal 2022.
- OPKO Health, Inc. operating lease, payments for fiscal 2022 was $16.27M, a 2.13% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.86M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $7.60M 10-Q/A · filed 2026-08-28 | $11.37M derived: sum of 3 quarters · filed 2026-08-28 | $14.52M derived: sum of 4 quarters · filed 2026-08-28 |
| 2026-03-31 | $3.73M 10-Q/A · filed 2026-08-28 | $7.50M derived: sum of 2 quarters · filed 2026-08-28 | $10.66M derived: sum of 3 quarters · filed 2026-08-28 | $14.91M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.93M derived: sum of 2 quarters · filed 2026-02-26 | $11.18M derived: sum of 3 quarters · filed 2026-08-28 | $14.64M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.16M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | $7.41M derived: sum of 2 quarters · filed 2026-08-28 | $10.87M 10-Q · filed 2025-10-29 | $13.30M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-06-30 | $4.25M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $7.71M 10-Q/A · filed 2026-08-28 | $10.15M derived: sum of 3 quarters · filed 2026-08-28 | $16.13M derived: sum of 4 quarters · filed 2026-08-28 |
| 2025-03-31 | $3.46M 10-Q/A · filed 2026-08-28 | $5.90M derived: sum of 2 quarters · filed 2026-08-28 | $11.88M derived: sum of 3 quarters · filed 2026-08-28 | $16.66M derived: sum of 4 quarters · filed 2026-08-28 |
| 2024-12-31 | $2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.42M derived: sum of 2 quarters · filed 2026-02-26 | $13.20M derived: sum of 3 quarters · filed 2026-02-26 | $17.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $10.77M derived: sum of 2 quarters · filed 2025-10-29 | $15.10M 10-Q · filed 2025-10-29 | $19.51M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $4.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $9.11M 10-Q · filed 2025-07-31 | $13.52M derived: sum of 3 quarters · filed 2025-07-31 | $17.27M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $4.33M 10-Q · filed 2025-05-01 | $8.74M derived: sum of 2 quarters · filed 2025-05-01 | $12.49M derived: sum of 3 quarters · filed 2025-05-01 | $16.57M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $8.16M derived: sum of 2 quarters · filed 2025-03-03 | $12.24M derived: sum of 3 quarters · filed 2025-03-03 | $16.11M 10-K · filed 2025-03-03 |
| 2023-09-30 | $3.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.83M derived: sum of 2 quarters · filed 2024-11-07 | $11.70M 10-Q · filed 2024-11-07 | $15.66M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $7.96M 10-Q · filed 2024-08-07 | $11.91M derived: sum of 3 quarters · filed 2024-08-07 | $15.90M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $3.87M 10-Q · filed 2024-05-07 | $7.83M derived: sum of 2 quarters · filed 2024-05-07 | $11.82M derived: sum of 3 quarters · filed 2024-05-07 | $15.86M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $7.94M derived: sum of 2 quarters · filed 2024-03-01 | $11.98M derived: sum of 3 quarters · filed 2024-03-01 | $16.27M 10-K · filed 2024-03-01 |
| 2022-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $8.02M derived: sum of 2 quarters · filed 2023-11-06 | $12.31M 10-Q · filed 2023-11-06 | $16.66M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $4.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $8.33M 10-Q · filed 2023-08-03 | $12.67M derived: sum of 3 quarters · filed 2023-08-03 | $18.47M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $4.29M 10-Q · filed 2023-05-03 | $8.63M derived: sum of 2 quarters · filed 2023-05-03 | $14.43M derived: sum of 3 quarters · filed 2023-05-03 | $16.67M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $10.14M derived: sum of 2 quarters · filed 2023-02-27 | $12.38M derived: sum of 3 quarters · filed 2023-02-27 | $16.63M 10-K · filed 2023-02-27 |
| 2021-09-30 | $5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.03M derived: sum of 2 quarters · filed 2022-11-08 | $12.28M 10-Q · filed 2022-11-08 | $16.12M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $6.48M 10-Q · filed 2022-08-04 | $10.33M derived: sum of 3 quarters · filed 2022-08-04 | $14.12M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $4.25M 10-Q · filed 2022-05-09 | $8.09M derived: sum of 2 quarters · filed 2022-05-09 | $11.88M derived: sum of 3 quarters · filed 2022-05-09 | $16.99M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $3.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.64M derived: sum of 2 quarters · filed 2022-03-01 | $12.74M derived: sum of 3 quarters · filed 2022-03-01 | $17.44M 10-K · filed 2022-03-01 |
| 2020-09-30 | $3.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $8.90M derived: sum of 2 quarters · filed 2021-10-28 | $13.60M 10-Q · filed 2021-10-28 | $18.64M derived: sum of 4 quarters · filed 2021-10-28 |
| 2020-06-30 | $5.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $9.80M 10-Q · filed 2021-07-29 | $14.85M derived: sum of 3 quarters · filed 2021-07-29 | $19.71M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $4.70M 10-Q · filed 2021-04-28 | $9.75M derived: sum of 2 quarters · filed 2021-04-28 | $14.61M derived: sum of 3 quarters · filed 2021-04-28 | $19.67M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $5.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $9.91M derived: sum of 2 quarters · filed 2021-02-18 | $14.97M derived: sum of 3 quarters · filed 2021-02-18 | $20.71M 10-K · filed 2021-02-18 |
| 2019-09-30 | $4.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $9.92M derived: sum of 2 quarters · filed 2020-10-29 | $15.66M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $10.80M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $5.74M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |